Volume 13, Number 2—February 2007
Research
Neutralizing Antibodies after Infection with Dengue 1 Virus
Gustavo Kourí*
, Mayling Alvarez*, Rosmari Rodriguez-Roche*, Lídice Bernardo*, Tibaire Montes†, Susana Vazquez*, Luis Morier*, Angel Alvarez*, Ernest A Gould‡, Maria G. Guzman* , and Scott B Halstead§
, Mayling Alvarez*, Rosmari Rodriguez-Roche*, Lídice Bernardo*, Tibaire Montes†, Susana Vazquez*, Luis Morier*, Angel Alvarez*, Ernest A Gould‡, Maria G. Guzman* , and Scott B Halstead§
Table 1
Dengue virus strains used in this study
| Serotype | Strain | Passage no.* | Place and year of isolation |
|---|---|---|---|
| DENV-1† | Angola | 4PC6/36 1PVero 1PC6/36 | Angola, 1988 |
| DENV-2‡ | A15/81 | 4PMB 4PC6/36 | Cuba, 1981 |
| DENV-2†‡ | I348600 | 4P C6/36 | Colombia, 1986 |
| DENV-3 | 116/00 | 3P C6/36 | Cuba, 2000 |
| DENV-4† | Dominica | 7P C6/36 | Dominica, 1981 |
**P, passage; C6/36, Aedes albopictus cell line; Vero, green monkey kidney cell line; MB, mouse brain.
†DENV, dengue virus; received from Robert Shope, University of Texas Medical Branch, Galveston, Texas, USA.
‡DENV-2, A15/81 strain (Asian genotype), DENV 2, I348600 (American genotype).
Page created: June 29, 2010
Page updated: June 29, 2010
Page reviewed: June 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.